Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03135756 · ClinicalTrials.gov registry record
Mechanisms of Anxiety and Depression Study
A clinical trial, sponsored by Palo Alto University.
- Completed
- Registry status
- 63
- Enrollment target
NCT03135756: Completed study, sponsored by Palo Alto University.
NCT03135756 is a clinical trial that has completed, run by Palo Alto University. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03135756 has completed, sponsored by Palo Alto University.
- COMPLETED
- Registry status
- 63 participants
- Enrollment target
Study Summary
Eligible participants will come in for three separate visits in which they will be interviewed, perform a variety of tasks, and undergo a non-invasive MRI scan. The investigators anticipate that (1) participants with anxiety and depression will likely perform differently than the healthy controls on cognitive tasks, (2) participants with anxiety and depression will likely show differences in brain functionality compared to the healthy controls, and (3) depression and anxiety likely share some underlying mechanisms.
Primary Outcome
Non-invasive MRI brain scan to see function and structure of brain
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2015-03-19 |
| Est. Completion | 2018-03-14 |
What the finished NCT03135756 record still lists
NCT03135756 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 63 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03135756 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03135756 about?
NCT03135756 is a clinical study titled "Mechanisms of Anxiety and Depression Study". Eligible participants will come in for three separate visits in which they will be interviewed, perform a variety of tasks, and undergo a non-invasive MRI scan. The investigators anticipate that (1) participants with anxiety and depression will likely perform differently than the healthy controls on...
What is the current status of trial NCT03135756?
This trial is currently completed. The enrollment target is 63 participants. The study started on 2015-03-19. Estimated completion is 2018-03-14.
Who is sponsoring clinical trial NCT03135756?
This trial is sponsored by Palo Alto University, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI